Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?

Kabat, Maciej; Bobkov, Ivan; Kumar, Suneel; Grumet, Martin

Kabat, Maciej; Bobkov, Ivan; Kumar, Suneel; Grumet, Martin.

Afiliación

Kabat M; W. M. Keck Center for Collaborative Neuroscience, Rutgers Stem Cell Research Center, Department of Cell Biology & Neuroscience, Rutgers University, Piscataway, New Jersey.
Bobkov I; W. M. Keck Center for Collaborative Neuroscience, Rutgers Stem Cell Research Center, Department of Cell Biology & Neuroscience, Rutgers University, Piscataway, New Jersey.
Kumar S; Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey.
Grumet M; W. M. Keck Center for Collaborative Neuroscience, Rutgers Stem Cell Research Center, Department of Cell Biology & Neuroscience, Rutgers University, Piscataway, New Jersey.

Stem Cells Transl Med ; 9(1): 17-27, 2020 01.

Article en En | MEDLINE | ID: mdl-31804767

Asunto(s)

Trasplante de Células Madre Mesenquimatosas/métodos; Ensayos Clínicos como Asunto; Historia del Siglo XXI; Humanos

Palabras clave

ClinicalTrials.gov; dose; intravenous; mesenchymal stromal cell

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas Límite: Humans Idioma: En Revista: Stem Cells Transl Med Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google